Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$13.15 - $20.45 $282,199 - $438,857
-21,460 Reduced 53.61%
18,573 $346,000
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $499,138 - $888,042
-24,661 Reduced 38.12%
40,033 $830,000
Q3 2021

Nov 10, 2021

SELL
$26.01 - $38.22 $548,472 - $805,945
-21,087 Reduced 24.58%
64,694 $2.07 Million
Q2 2021

Aug 11, 2021

SELL
$29.97 - $37.17 $206,403 - $255,989
-6,887 Reduced 7.43%
85,781 $2.64 Million
Q1 2021

May 14, 2021

SELL
$29.24 - $42.03 $902,785 - $1.3 Million
-30,875 Reduced 24.99%
92,668 $3.12 Million
Q4 2020

Feb 16, 2021

SELL
$35.35 - $50.67 $107,181 - $153,631
-3,032 Reduced 2.4%
123,543 $4.46 Million
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $4.36 Million - $5.78 Million
-121,293 Reduced 48.93%
126,575 $4.66 Million
Q2 2020

Aug 10, 2020

BUY
$45.06 - $67.74 $6.91 Million - $10.4 Million
153,366 Added 162.29%
247,868 $11.2 Million
Q1 2020

May 08, 2020

BUY
$40.01 - $73.97 $1.94 Million - $3.59 Million
48,524 Added 105.54%
94,502 $4.48 Million
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $714,001 - $1.11 Million
-13,533 Reduced 22.74%
45,978 $3.59 Million
Q4 2018

Feb 12, 2019

SELL
$22.8 - $33.93 $4.88 Million - $7.26 Million
-213,823 Reduced 78.23%
59,511 $1.72 Million
Q3 2018

Nov 09, 2018

BUY
$29.75 - $43.08 $7.12 Million - $10.3 Million
239,310 Added 703.36%
273,334 $9.95 Million
Q2 2018

Aug 13, 2018

BUY
$21.96 - $39.94 $747,167 - $1.36 Million
34,024 New
34,024 $1.29 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.